You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Table INF-1. Prevalence of HIV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country
| Country or region | % Infected (1) | ||||||
|---|---|---|---|---|---|---|---|
| Year | Number tested | National samples | Sub-national samples | Study design (2) | Setting/comments (3, 4, 5) | References | |
| Belgium | 2010 | 394 | : | 3.4-6.0 | DT ; SR | LTS, DTC; serum | 27 ; 28 ; 99 |
| Bulgaria | 2010 | 1258 | : | 2.2 | DT | DTC; NSP; LTS; serum | 7c |
| Czech Republic | 2010 | 4538 | 0.0-0.6 | : | DT ; SR | STI, OHC, HTC, DTC, LTS, NSP, GPS; PHL; serum, saliva, capillary blood | 28 ; 31 ; 32 |
| Denmark | 2006 | 188 | 2.1 | : | SP (UAT) | ODD, 5 sites; IDUnk | 7 |
| Germany | 2007 | 1394 | 3.4 | : | DT | ODD; autopsy rates 62%; Drug related deaths throught accident, long term effects, suicide. IDUnk | 30 ; 31 |
| Estonia | 2005 | 449 | : | 54.3 - 89.9 | DT | LTS; dried blood spots | 4 |
| Ireland | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| Greece | 2010 | 2028 | 0.7-0.8 | 0.0-3.6 | DT;SP | DTC, LTS, PHL, OHC, PRI, OTH; serum | 1 ; 2 ; 9 ; 18 |
| Spain | 2009 | 7143 | 32.3 | : | DT | DTC; PRI; serum | 39 ; 40 ; 41 |
| France | 2006 | 698 | : | 5.1-8.0 | SP (UAT) ; SR | NSP, LTS, STR; saliva | 19 ; 21 |
| Italy | 2009 | 60057 | 11.5 | 0.9-26.4 | DT | DTC, 533 sites; serum IDUnk | 47 ; 48a ; 48b |
| Cyprus | 2010 | 355 | 0.0-1.3 | : | DT ; SR | DTC, PRI; serum | 10 ; 11 |
| Latvia | 2010 | 1939 | 6.3 | 2.9-19.8 | DT ; SP ; SR | NSP, PRI; rapid HIV tests (capillary blood from finger), dried blood spots | 13 ; 14 ; 15 ; 17 ; 18 |
| Lithuania | 2010 | 720 | : | 0.0-21.4 | SR | NSP | 14 |
| Luxembourg | 2010 | 164 | 2.4 | : | SR | DTC, OHC, PRI; serum | 8 ; 11 |
| Hungary | 2009-10 | 1222 | 0.0 | 0.0 | SP ; DT | DTC, NSP, PRI; serum, dried blood spots | 19 ; 20b ; 21 ; 23 |
| Malta | 2010 | 118 | 0.0 | : | DT | PHL, STI, ANT, OHC; serum | 5 ; 7; 8 |
| Netherlands | 2010 | 67 | : | 0.0 | DT ; SP | DTC ; serum | 35 ; 36 |
| Austria | 2010 | 780 | 0.7-5.3 | 0.0-0.8 | DT | NSP, LTS, ODD, DTC; serum | 2 ; 12 ; 13 ; 14 |
| Poland | 2009-10 | 842 | 6.8 | 8.9-26.4 | DT ; SP | PHL, OTH, LTS; serum | 10 ; 11 ; 12 ; 20 |
| Portugal | 2009-10 | 6348 | 4.9-17.2 | : | DT ; SP | DTC; serum, dried blood spots | 30 ; 31 |
| Romania | 2009-10 | 737 | 4.2 | 1.1 | SR ; SP(UAT) | DTC, NSP, LTS, STR; serum, dried blood spots, urine | 2 ; 4 ; 5 ; 6 ; 7 |
| Slovenia | 2010 | 514 | 0.4 | 0.4 | SP (UAT) ; DT | NSP, DTC; saliva, serum | 5 ; 6 ; 8 ; 9 |
| Slovakia | 2010 | 434 | 0.3 | 1.6 | DT ; SP | DTC, ODD, PRI, HTC; serum | 12 ; 13 ; 14 ; 15 |
| Finland | 2009 | 684 | 0.7 | SP (UAT) | NSP; saliva | 8 | |
| Sweden | 2009 | 250 | : | 2.0 | DT | PRI; serum | 13 |
| United Kingdom | 2010 | 3288 | : | 0.0-4.3 | SP (UAT) | DTC, NSP, LTS, OTH; dried blood spots, saliva or other oral fluid | 50 ; 51 ; 53 ; 54 ; 65 |
| Croatia | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| Turkey | 2010 | 644 | 0.5 | : | DT | DTC; serum | 3 |
| Norway | 2010 | 4714 | 2.4 | 0.6 | SP | NSP, DTC, LTS; serum | 16 ; 21 , 23 ; 25 |
Notes:
This summary table gives a global overview of HIV prevalence in IDUs in the EU, 2010 or most recent year available. Data for more than one year are combined if they clearly improve generalisability (e.g. national data, out-of-treatment data). Prevalence in this table should not be compared with previous versions to follow changes over time, as inclusion of sources may vary according to data availability. For time trends see Tables:INF-108, INF-109, and INF-110
n.a. = not available
(1) The figures show estimates (or range of estimates) from National and/or Sub-National level samples.
(2) Self-reported test results are less reliable than biological test results.
DT: Diagnostic testing; SP: Seroprevalence study; SP-UAT: Seroprevalence study with unlinked anonymous testing; RDS: Respondent-driven sampling; SR: Data (partly) based on self reported test results.
(3) Having health problems is one selection criterion for admission to drug treatment in some countries or cities, due to long waiting lists or special programmes for infected IDUs, and this may result in upward bias of prevalence. Prevalence from treatment data should therefore be interpreted in combination with non-treatment data. On the other hand, data from Italy and Portugal include non-IDUs and may thus underestimate prevalence in IDUs.
(4) § IDUnk = IDU status not known, prevalence in IDUs is likely to be underestimated.
(5) ODD = Overdose Deaths; DEM = Drug Emergencies; DTC = Drug Treatment Centres; NSP = Needle Exchanges; LTS = Low-Threshold Services; PHL = Public Health Laboratories; STI = STI Clinics; ANT = Antenatal Clinics; OHC = Other Hospital or Clinics; PRI = Prisons; ARR = Arrests; GPS = General Practitioners; HTC = HIV Testing Centres; STR = Street; OTH = Other.
Sources:
See Table INF-108 .
For references see Table INF-0. Bibliographic References-Part A: References for prevalence data